Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on April 10, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Effective April 7, 2026, Intellia adopted Fourth Amended and Restated By-laws.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Effective April 7, 2026, Intellia adopted Fourth Amended and Restated By-laws
- Shareholders may cure facial deficiencies in timely nomination or proposal notices
- Company must notify shareholders of facial deficiencies, potentially reducing procedural challenges
- Federal district courts designated exclusive forum for Securities Act and Exchange Act claims absent company consent
- Federal forum provision may increase litigation predictability while raising shareholder access considerations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.